You are here: Industry Insights > BMS

News List

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients pharmatimes
May 25, 2021
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
Exscientia signs $1.2bn AI drug discovery deal with BMS pharmaceutical-technology
May 21, 2021
Bristol-Myers Squibb (BMS) and Exscientia have signed a partnership agreement to leverage artificial intelligence (AI) for the discovery of small molecule drug candidates in various therapeutic areas, including oncology and immunology.
Agenus and BMS Announce License for Anti-TIGIT Bispecific Antibody Program americanpharmaceuticalreview
May 19, 2021
Bristol-Myers Squibb Company and Agenus Inc. have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a ...
NICE nod for BMS’ Opdivo in advanced oesophageal cancer pharmatimes
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer (OSCC).
BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
BMS, Evotec Extend Targeted Protein Degradation Alliance contractpharma
April 27, 2021
Bristol Myers Squibb has exercised its option to extend its partnership with Evotec SE in the field of targeted protein degradation, triggering an undisclosed payment to Evotec.
BMS to invest in new cell therapy manufacturing site in Europe pharmatimes
April 26, 2021
Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.
Opdivo plus Cabometyx approved in the EU for advanced renal cancer pharmatimes
April 01, 2021
The European Commission (EC) has authorised Bristol Myers Squibb’s (BMS) Opdivo plus Ipsen’s Cabometyx as a first-line treatment for advanced renal cell carcinoma (aRCC).
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma pharmatimes
March 31, 2021
Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma.
BMS Expands Cell Therapy Manufacturing Capabilities contractpharma
March 02, 2021
New state-of-the-art cell therapy manufacturing facility under construction to expand global footprint.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page